News

The parntership allows PRECOS to validate RCT’s existing research using its validated patient relevant cancer models like in vitro 2D and 3D assays, in vivo therapeutic evaluations and

CSPN offers specialty pharmacy services including mail distribution, clinical services, therapy management and web-based reporting. MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the

The tie up is focused on leveraging drug discovery platform of Intercept that is based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other

The company has posted a net loss of $5m for the second quarter of 2011, compared to $2.35m for the same period in 2010. The company’s loss from

The newly issued patent, namely, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ includes the usage of oral lactoferrins, including talactoferrin, to treat cancer. The

The TGA Transparency Review Report comprises recommendations relating to the labelling of medicines. The TGA will be considering the submissions to the review and the relevant sections of

In its CRL, the FDA has rejected to approve the drug in its present form and has requested information related to the product quality or CMC matters. Additionally,

As per the terms of the CRADA, Division of Cancer Treatment and Diagnosis (DCTD) of NCI intends to sponsor PCI-32765 Phase 1 and Phase 2 trials in certain

The company expects to start operations in the new formulation plant in the second half of 2012. Lonza Nutrition business unit head Roman Quinter said by developing ready-made